ACE inhibitors and ARBs: Managing potassium and renal function
2019年9月1日 · ACE inhibitors and ARBs reduce proteinuria by lowering the intraglomerular pressure, reducing hyperfiltration. These drugs tend to raise the serum potassium level and reduce the glomerular filtration rate (GFR). Monitoring the serum potassium and creatinine levels and the GFR is therefore imperative.
Hyperkalemia After Initiating Renin–Angiotensin System …
2017年7月19日 · Concerns about hyperkalemia limit the use of angiotensin‐converting enzyme inhibitors (ACE ‐I) and angiotensin receptor blockers (ARB s), but guidelines conflict regarding potassium‐monitoring protocols. We quantified hyperkalemia monitoring and risks after ACE ‐I/ ARB initiation and developed and validated a hyperkalemia susceptibility score.
Hyperkalemia Associated with Use of Angiotensin‐Converting …
2011年1月26日 · ACEi and ARB are effective therapeutic agents used in a variety of clinical scenarios. However, related to their effects on the renin–angiotensin–aldosterone system, their use can be associated with hyperkalemia, particularly in …
Antihypertensive Medications and the Prevalence of Hyperkalemia …
Clinical trial data suggests that the risk of hyperkalemia associated with RAAS inhibition ranges from 2%-10% in patients with hypertension, heart failure, and CKD, and that hyperkalemia risk may be slightly lower with ARBs compared to ACEIs.
Hyperkalemia associated with use of angiotensin-converting …
The aims of this article are to review the current understanding of hyperkalemia associated with angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) therapy. This includes reviewing the pathophysiology of how these agents affect potassium handling within the …
Effects of an ACE inhibitor or angiotensin receptor blocker on ...
Background: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) have shown numerous benefits to the cardiovascular system. However, using both drugs is associated with hyperkalemia, especially in end-stage renal disease (ESRD) patients.
Hyperkalemia Associated With Inhibitors of the Renin-Angiotensin …
2008年10月14日 · Although inhibitors of the renin-angiotensin-aldosterone System (RAAS) reduce renal potassium excretion, elevations of serum potassium associated with use of these agents in heart failure patients are typically modest (<1 mEq/L), and severe or life-threatening hyperkalemia is thought to be uncommon. 2 However, several patient factors associated ...
Background-—Concerns about hyperkalemia limit the use of angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARBs), but guidelines conflict regarding potassium-monitoring protocols. We quantified hyperkalemia monitoring
A comparative study assessing the incidence and degree of hyperkalemia …
2021年10月14日 · Our study demonstrates that ACEI is associated with both a higher incidence and greater degree of hyperkalemia than ARB, especially among patients with CKD. This conclusion is based on a...
Hyperkalemia management: a multidisciplinary expert panel
2024年11月27日 · Hyperkalemia is a potentially life-threatening condition frequently encountered in clinical practice, particularly among patients with chronic kidney disease, heart failure, diabetes, and hypertension and those undergoing treatment with renin–angiotensin–aldosterone system inhibitors (RAASi). The management of chronic and acute hyperkalemia is complex and requires timely intervention to ...
- 某些结果已被删除